A

AGC Biologics

End-to-end biopharma CDMO for gene therapies

Business Development Associate

Full-TimeUpdated on 10/23/2026Deadline 10/29/26
$108.1k - $148.6k
Junior, Mid
Bachelor's
Massachusetts, USA
RemoteApplicants must be based in the Boston, MA area.
Sales & Account ManagementSales Development Representative

About the job

Requirements
  • Requires 1–3 years of experience in business development, inside sales, or a related commercial role, preferably in the CDMO, CRO, or broader life sciences or biopharmaceutical sector.
  • Requires a bachelor's degree in Life Sciences, Biochemistry, Biotechnology, Business Administration, or a related field.
  • Requires a demonstrated track record of proactive outreach and lead qualification, with the ability to generate and manage a high-volume pipeline across multiple accounts and geographies.
  • Requires the ability to craft personalized, high-impact outreach across email, phone, and LinkedIn that generates responses and opens doors with scientific and commercial stakeholders.
  • Requires proficiency with customer relationship management platforms such as Salesforce and standard business tools such as Microsoft Office Suite, with discipline around pipeline tracking and data integrity.
  • Requires written and verbal communication skills to distill complex technical content into clear, audience-appropriate messaging.
  • Requires willingness and ability to travel domestically approximately 15% for industry events and internal engagements.
  • Requires being based in the Boston, Massachusetts area.
Responsibilities
  • Identify, research, and qualify new business leads across North America as the primary prospecting resource for the North American Business Development team, working with Market Intelligence and Marketing teams.
  • Conduct proactive outreach by phone, email, LinkedIn, and industry events to engage prospective clients and generate a pipeline of development and manufacturing opportunities across North America.
  • Partner with North American BD Directors and Senior Directors to prioritize target accounts, coordinate outreach strategies, and hand off qualified opportunities.
  • Build and maintain relationships in the Boston/Cambridge biotech and pharmaceutical community, represent the company at local events, and increase brand awareness in the Boston biotech ecosystem.
  • Coordinate, attend, and represent the company at Boston-area industry events and networking functions, North American conferences, and trade shows; capture leads and advance relationships for the broader North American team.
  • Communicate the company’s technical and operational capabilities to decision-makers and scientific stakeholders at prospective organizations.
  • Maintain accurate, up-to-date records of prospect interactions, pipeline activity, and opportunity status in CRM systems such as Salesforce, ensuring visibility and timely follow-up across the North American team.
  • Collaborate with Marketing on North American commercial initiatives, including campaign execution, conference preparation, and targeted lead-generation activities.
  • Gather and synthesize market intelligence from customer interactions, and share insights with BD and commercial leadership to inform North American go-to-market strategy.
  • Deliver qualified opportunities aligned with company growth strategies and leadership expectations.
Desired Qualifications
  • Familiarity with biologics drug development processes, including microbial expression systems such as E. coli or yeast, mammalian expression systems such as CHO or HEK, or nucleic acids.
  • Prior experience in a CDMO, CRO, or biopharmaceutical company in a commercial or scientific role.
  • Experience with lead-generation and sales-engagement tools such as ZoomInfo, LinkedIn Sales Navigator, Outreach, or Salesloft.
  • Understanding of the drug development lifecycle from early-stage research through commercial manufacturing.
  • An established network within the Boston/Cambridge biotech and pharmaceutical community.

About the company

A

AGC Biologics

View
cbWebsite

AGC Biologics is a global contract development and manufacturing organization (CDMO) that provides end-to-end development and production services for biopharmaceuticals, including therapeutic proteins, plasmid DNA, viral vectors, and engineered cells. It moves projects from early development to full-scale manufacturing and offers fast-track capabilities for orphan drugs and rare diseases, backed by cGMP-compliant facilities across the U.S., Europe, and Asia. The company differentiates itself with an international footprint, strict regulatory quality standards, and a focus on delivering accelerated timelines for complex therapies like cell and gene therapies. Its goal is to help biopharma partners bring new treatments to market efficiently and safely through integrated development and manufacturing solutions.

Company Size

1,001-5,000

Company Stage

Acquired

Total Funding

$557.7M

Headquarters

Bothell, Washington

Founded

2001

Get referred to AGC Biologics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 28, 2026 Yokohama won a hundreds-of-millions commercial manufacturing deal.
  • September 24, 2026 Flen Health chose AGC for recombinant enzyme GMP manufacturing.
  • May 26, 2026 Teikoku Seiyaku tapped AGC for rhMMP-7 clinical manufacturing.

What critics are saying

  • AGC will close Boulder and Longmont, eliminating 267 Colorado jobs by December 31, 2026.
  • Autolus signed a 10-year lentiviral deal, concentrating critical vector supply in one contract.
  • If Yokohama misses 2027 GMP start, the biggest growth engine stalls.

What makes AGC Biologics unique

  • AGC Biologics runs microbial and mammalian manufacturing across Seattle, Copenhagen, Heidelberg, Chiba, Yokohama.
  • It is the only CDMO with microbial manufacturing on three continents.
  • Its Yokohama network pairs cell therapy, mRNA, and mammalian scale-up in one campus.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

9%

2 year growth

12%
GlobeNewswire
Sep 24th, 2026
Flen Health chooses AGC Biologics to manufacture recombinant enzymes for next-generation wound treatment.

Flen Health chooses AGC Biologics to manufacture recombinant enzymes for next-generation wound treatment. Heidelberg site to lead GMP development of lactoperoxidase and glucose oxidase for Phase II clinical trials. HEIDELBERG, Germany, Sept. 24, 2026 (GLOBE NEWSWIRE) - Belgian biopharmaceutical company Flen Health has selected AGC Biologics as their CDMO partner to provide process development, scale-up, and GMP manufacturing services for a new and improved wound and skin healing product. Manufacturing Services to Support Regulatory Submissions, Clinical Trials "We're thankful Flen Health has entrusted us with this next chapter." "Patients with diabetic foot ulcers need better treatment options," "By combining our novel recombinant enzyme platform with AGC Biologics' manufacturing expertise, we are accelerating the development of a promising new..." "As we now advance into full GMP development and manufacturing, we are building on a successful feasibility program we initiated with Flen Health in July..." With cell line development from myBIOS complete, AGC Biologics' Heidelberg, Germany facility will partner for the next stage of development and clinical-scale manufacturing of two recombinant proteins, lactoperoxidase and glucose oxidase, the enzymatic components at the core of the wound treatment's novel mechanism of action. Following the technology transfer, AGC Biologics will conduct microbial manufacturing at 100-liter and 1,000-liter scale using the Pichia pastoris expression system, in support of Flen Health's planned Investigational New Drug submission and Phase II clinical trials. A Novel Combination Product Flaminal(R) has been used clinically for 25 years in European markets as a topical enzyme-alginate gel for difficult-to-heal wounds. Classified as a medical device, the therapeutic approach combines a recombinant enzyme system within an alginate matrix to accelerate wound healing. Flen Health is now advancing an improved, recombinant version of the product as part of its strategic entry into the U.S. market, which has seen limited changes to the chronic and acute wound care sector in recent years. Addressing a Serious Diabetes Complication Diabetic foot ulcers remain one of the most undertreated complications in chronic wound care, affecting up to 25% of diabetic patients in their lifetime with an annual cost of $13 billion to the US healthcare system. Diabetic foot ulcers are the leading cause of lower extremity amputations among people with diabetes, accounting for about 85% of such procedures. Globally, 10.2% of the population are living with diabetes and the prevalence of the disease continues to rise, increasing the risk of non-healing foot ulcers and further straining healthcare systems. Effective wound repair in DFUs is challenged by disrupted cell communication, impaired inflammatory responses, and a hostile healing environment. The Next Chapter for Enzyme-based Wound Therapies While Flen Health's Phase 0 human study will utilize current food-grade enzyme formulations, the strategic transition to AGC Biologics' pharma-grade recombinant enzymes will occur ahead of Phase II clinical trials, applying deep expertise in a world-class GMP facility in preparation for U.S. regulatory submissions. "Patients with diabetic foot ulcers need better treatment options," said Georges Sollie, CEO of Flen Health. "By combining our novel recombinant enzyme platform with AGC Biologics' manufacturing expertise, we are accelerating the development of a promising new therapeutic approach." "As we now advance into full GMP development and manufacturing, we are building on a successful feasibility program we initiated with Flen Health in July 2025. That is exactly the pattern we pride ourselves on, building trust and mutual collaboration with our customers," said Dieter Kramer, Managing Director, AGC Biologics Heidelberg. "We're thankful Flen Health has entrusted us with this next chapter." In addition to the Heidelberg location, AGC Biologics' global microbial manufacturing network includes facilities in Copenhagen, Denmark; Seattle, USA; and Chiba, Japan. Frequently Asked Questions (FAQs): Will the recombinant LPO/GOX product require a traditional IND, a device submission, or some other regulatory coordination with the FDA? Flen Health participated in an INTERACT meeting with the FDA in January 2026 to receive feedback on their Chemistry, Manufacturing, and Controls development plan. This enables them to prepare for an IND submission. How does the new recombinant version differ from the current Flaminal product? The current Flaminal product on the market utilizes food-grade enzymes within an alginate environment to effectively treat difficult-to-heal wounds and accelerate the healing process. With the new recombinant version, AGC Biologics will manufacture the lactoperoxidase and glucose oxidase drug substances to GMP and pharma-grade standards to support classification of the product as a biologic in the United States. Does AGC Biologics provide strain development? AGC Biologics offers full strain development for Escherichia coli expression systems. For this program, Flen Health partnered with myBIOS to provide Pichia pastoris strain cell line development. myBIOS specializes in methanol-free, inducible recombinant protein production using P. pastoris, enabling safer, more sustainable, and cost-efficient manufacturing. myBIOS supports customers in strain engineering and early-stage process development, while its myPICHIA(R) platform provides a comprehensive toolbox for in-house protein production. AGC Biologics has experience working with partners to provide process development for multiple expression system host cells (E. coli, P. pastoris with or without methanol induction, Pseudomonas fluorescens, Bacillus, and Lactobacillus casei). What did the feasibility program launched in July 2025 include: strain screening, cell-line development, fermentation, purification, formulation, analytics, or all of these? The feasibility stage conducted at the AGC Biologics site in Heidelberg for Flen Health included comprehensive process transfer, upstream and downstream process development, analytical method implementation, and dedicated project management for recombinant lactoperoxidase and glucose oxidase programs. By focusing on optimizing fermentation, purification, and analytical frameworks, this strategic partnership lays a solid groundwork for future wound and skin healing solutions. Will AGC Biologics support CMC documentation for the IND, including process descriptions, analytical methods, specifications, validation plans, and stability data? Similar to other customer programs, AGC Biologics will support all required regulatory documentation for the IND submission, building on best practices developed through other submissions and providing its regulatory expertise at every stage. What is the regulatory history of the AGC Biologics Heidelberg site? AGC Biologics has a strong regulatory track record. The 100+ successful audits and inspections conducted at AGC Biologics help the CDMO continuously hone its quality and compliance culture and systems. The AGC Biologics Heidelberg site has received regulatory approvals from agencies such as the FDA, EMA, and PMDA. Heidelberg's inspection history over the last ten years includes routine inspections from the FDA and Germany's Regierungspräsidium Tübingen, all with no critical or major findings. About Flen Health Flen Health is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in wound care. Founded in 2000 and headquartered in Kontich, Belgium, the company has more than 25 years of experience delivering trusted wound and skin healing solutions across Europe and in more than 40 countries worldwide. Flen Health is now leveraging this expertise to bring its novel therapeutics to the U.S. market. For more information, visit www.flenhealth.com. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as Dixon Mitchell work side-by-side with its clients and partners, to provide friendly and expert services. Dixon Mitchell provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Its global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

Ochre Digi Media Pvt. Ltd.
Jul 29th, 2026
AGC Biologics lands commercial manufacturing agreement for Yokohama site worth hundreds of millions of dollars.

AGC Biologics lands commercial manufacturing agreement for Yokohama site worth hundreds of millions of dollars. Wednesday, July 29, 2026 Ahead of the official opening of AGC Biologics' Yokohama site, an international biopharmaceutical company has already secured half of the facility's mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. The Contract Development and Manufacturing Organization (CDMO) will leverage its new Yokohama facility to manufacture a minimum of 35 batches per year of five biopharmaceutical products for the undisclosed customer, securing a reliable global supply chain for patients worldwide. The agreement includes process transfer, scale-up, regulatory validation, and future commercial production. The customer will pursue multiple regulatory approvals with the EMA, FDA, MHRA, and PMDA. The aggressive manufacturing timeline includes four process performance qualifications (PPQ) campaigns in the first two years. Securing commercial production in Japan reflects a broader industry shift toward supply chain resilience, as global biopharmaceutical developers increasingly prioritize established, geopolitically stable manufacturing partners with locations that mitigate geopolitical, regulatory and trade risks. "AGC Biologics has the largest global network of single-use manufacturing capacity by volume outside of China, but that's not the full story," said Alberto Santagostino, President and CEO of AGC Biologics. "The market is demanding capable, reliable manufacturing partners with global quality standards and geographic flexibility. This agreement reflects the strength of our network, our single-use expertise, and the strategic role Japan can play in resilient biologics supply chains. Our newest Japan site in Yokohama synthesizes all our network learning in a location of increasing interest, and that carries the intrinsic cultural value of manufacturing quality and effective delivery." Once operational in 2027, the Yokohama site will deploy four 2,000-liter Cytiva single-use bioreactors and two 5,000-liter Thermo Fisher Scientific DynaDrive single-use bioreactors, adding 18,000 liters to AGC Biologics' existing capacity of single-use technology for biologics manufacturing. Select customers and guests are scheduled to be provided with the opportunity to visit the new site in December 2026, when construction is completed. "Securing a major commercial partner for Yokohama before the site is operational is a strong signal of confidence in what this facility will offer," said Tadashi Murano, President of AGC Life Science Company. "With the site located adjacent to the AGC Yokohama Technical Center, biopharmaceutical developers are understanding that choosing a CDMO with an established innovation ecosystem in Japan is a smart outsourcing strategy." The AGC Biologics' Yokohama site was part of the biomanufacturing investments made by Japan's Ministry of Economy, Trade and Industry in 2022. These strategic investments are designed to expand domestic production and reinforce Japan's position as a highly trusted, long-term biologics partner for life sciences industries within allied nations. Services available in Yokohama starting in 2027 will include: * Mammalian development and GMP manufacturing, with two downstream lines and flexible single-use bag capacity of 18,000 liters. * Cell therapy services with six clean rooms. * Messenger RNA (mRNA) development and manufacturing with 2 IVT, two purification lines, and two LNP lines. With existing cGMP manufacturing locations in the U.S., Japan, and Europe, AGC Biologics' track record will help kick off the manufacturing operation in Yokohama, utilizing the experience of: * More than three decades of GMP experience. * 100 successful regulatory inspections. * More than 30 commercial products launched, which received more than 100 separate regulatory agency approvals. * More than 400 products developed and manufactured for over 250 different customers. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as Pharma Focus Asia work side-by-side with its clients and partners, to provide friendly and expert services. Pharma Focus Asia provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Its global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

The Mirror Democrat and Savanna Times-Journal
May 26th, 2026
AGC Biologics to manufacture Teikoku Seiyaku's rhmmp-7 drug substance.

AGC Biologics to manufacture Teikoku Seiyaku's rhmmp-7 drug substance. * 7 hrs ago HEIDELBERG, Germany and CHIBA, Japan, May 26, 2026 (GLOBE NEWSWIRE) - AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 (rhMMP-7), to treat lumbar disc herniation. "Partnering with AGC Biologics was a clear choice. Their team has a proven track record in microbial manufacturing, and their global presence gives us the flexibility and security we need," said Dr. Hiroyuki Kubo, Director and Executive Officer at Teikoku Seiyaku. "We value their collaborative spirit and working together will be instrumental in bringing this important new therapy to patients." Development and GMP manufacturing for clinical trials Under the agreement, AGC Biologics will leverage its global network, with initial cell bank creation activities taking place at its Microbial Center of Excellence in Heidelberg, Germany. The project will then transition to the AGC Biologics' facility in Chiba, Japan, for process development and GMP manufacturing to support clinical trials. "Our role here in Heidelberg is to be a reliable and collaborative partner from the very beginning, applying our microbial development experience to build a robust foundation for this therapy," said Dieter Kramer, General Manager of the AGC Biologics Heidelberg site. "We have a 40-year-long tradition of helping projects advance and are well accustomed to partnering with other sites in our network to provide a steady journey towards GMP manufacturing." "We are delighted to support the Teikoku Seiyaku team on such an innovative project. It's a privilege to support their vision for a therapy that could offer a new, less invasive option for patients," said Susumu Zen-In, General Manager of the AGC Biologics Chiba site. A CDMO with a stable, global network This partnership highlights AGC Biologics' unique position as the only CDMO offering microbial manufacturing on three continents - Asia (Chiba, Japan), North America (Seattle, USA), and Europe (Heidelberg, Germany and Copenhagen, Denmark). This global network provides supply chain security and flexibility, allowing drug developers to de-risk their journey from clinical to commercial stages in a shifting geopolitical landscape. Frequently Asked Questions (FAQs): For a drug developer, why is a global manufacturing network important for supply chain security? A global network provides crucial flexibility and de-risks the supply chain by offering geopolitical stability and redundancy of supply. It allows for efficient tech transfer between sites with harmonized quality systems, offers multi-continent production options to meet regional market demands, and ensures business continuity. With facilities in the U.S., Europe, and Asia, AGC Biologics helps partners build a resilient manufacturing strategy that is not dependent on a single site or region. How is AGC Biologics investing to meet future microbial demand? AGC Biologics is committed to strategic growth that aligns with market needs. The company has brought a new microbial line online in the U.S. to support reshoring initiatives and is offering innovative capacity reservation models at its Heidelberg site in 10,000 L scale to provide long-term security for late-phase and commercial products. This is in addition to the extensive, established capabilities at its Copenhagen and Chiba sites, ensuring partners have access to robust, global capacity now and in the future. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as Mycarrollcountynews work side-by-side with its clients and partners, to provide friendly and expert services. Mycarrollcountynews provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Its global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. About Teikoku Seiyaku Founded in 1848, Teikoku Seiyaku is dedicated to its mission "For a World Without Pain", leveraging its expertise in transdermal absorption technology. Teikoku Seiyaku develops, manufactures, and markets anti-inflammatory and analgesic patches, narcotic drugs for medical use, and other pharmaceutical products.

Associated Press
May 4th, 2026
Novelty Nobility partners with AGC Biologics to advance bispecific antibody candidate NN4101

Novelty Nobility, a clinical-stage South Korean biotech company, has expanded its manufacturing agreement with AGC Biologics to advance its bispecific antibody drug candidate NN4101 through process development and GMP manufacturing at AGC Biologics' Chiba, Japan facility. The collaboration follows successful cell line development completed in Copenhagen, Denmark. NN4101 is a first-in-class bispecific antibody targeting neovascular retinal diseases, combining a fully human anti-c-Kit monoclonal antibody with a VEGF trap. The partnership leverages AGC Biologics' global network across the US, Europe and Asia. AGC Biologics is expanding its Japanese operations with a new state-of-the-art facility in Yokohama, designed to offer large-scale GMP manufacturing using single-use bioreactor technology to meet growing regional and global demand.

ConnectWeb
May 4th, 2026
Novelty Nobility taps AGC Biologics to further develop bispecific drug candidate.

Novelty Nobility taps AGC Biologics to further develop bispecific drug candidate. AGC Biologics, Inc. Successful partnership continues as bispecific antibody candidate moves to GMP manufacturing; project highlights Japan's advanced capabilities in bioprocessing and AGC Biologics' expanding global network CHIBA, Japan, May 04, 2026 (GLOBE NEWSWIRE) - Novelty Nobility, a clinical-stage biotech company based in South Korea, expanded its manufacturing agreement with AGC Biologics, your friendly CDMO expert, to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics' facility in Chiba, Japan. This second partnership, continued from the last year, underscores the successful track record and deep expertise AGC Biologics provides for developing complex biologics. The project leverages AGC Biologics' global network, having successfully completed cell line development in Copenhagen, Denmark. The program is now on track for a seamless tech transfer to the Chiba site for the next critical manufacturing stages. "AGC Biologics has proven to be an ideal manufacturing partner for advancing our most complex programs. Their seamless global network - from cell line development to GMP manufacturing - gives us the confidence to move NN4101 forward with speed and precision." said Sang Gyu Park, CEO of Novelty Nobility. "We believe this bispecific antibody has the potential to offer a truly differentiated treatment option for patients with neovascular retinal diseases." Novelty Nobility's bispecific antibody drug candidate NN4101 is a first-in-class bispecific antibody intended for the treatment of neovascular retinal diseases. It uniquely connects a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap. "Our continued partnership with Novelty Nobility is a testament to the trust and confidence customers have in our technical expertise and our global network's capabilities," said Tadashi Murano, President of the AGC Life Science Company. "Our mammalian expression teams are adept at handling complex proteins, and we are a world leader in applying flexible, single-use bioreactor technology. We are proud to support Novelty Nobility as they advance this innovative candidate toward the clinic." The project highlights the power of AGC Biologics' integrated global facility network, offering customers a seamless experience by combining world-class expertise with a strong regional presence. To further support growing demand in the region and globally, AGC Biologics is expanding its footprint in Japan with a new state-of-the-art facility in Yokohama. The Yokohama site is designed to utilize the latest single-use bioreactor technology to offer large-scale GMP manufacturing, making it one of the most advanced facilities of its kind in Japan. "When clients work with us, they tap into our entire global network which brings teams together for a seamless experience," noted Susumu Zen-in, Senior Vice President and General Manager of AGC Biologics' Chiba site. "This approach is creating wins for our partners and for AGC Biologics throughout the APAC region. The upcoming capacity at our new Yokohama site will only strengthen our ability to meet the global demand for vital biopharmaceuticals." About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as Connectweb work side-by-side with its clients and partners, to provide friendly and expert services. Connectweb provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Its global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. About Novelty Nobility Novelty Nobility is a clinical-stage biotech company driven by a mission to maximize the potential of therapeutic antibodies. The company is dedicated to developing next-generation treatments for immunology and inflammatory diseases. Leveraging its proprietary fully human antibody discovery platform, PREXISE(R)-D, together with deep expertise in protein engineering, Novelty Nobility is advancing a diverse pipeline of monoclonal antibodies (mAb), bispecific antibodies (bsAb), and antibody-drug conjugates (ADC) - modalities where scientific novelty translates into meaningful benefits for patients.